ArticleClinicoEconomics and outcomes research : CEOR2018

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative.

Giorgio L Colombo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.